Диссертация (1139774), страница 24
Текст из файла (страница 24)
2011. - V. 59(8). - P.1477-1483.112. Frackiewicz E.J., Sramek J.J., Herrera J.M., Kurtz N.M., Cutler N.R. Ethnicityand antipsychotic response // Annals of Pharmacotherapy. - 1997. - V. 31(11). - P.1360-69.145113. Freudenreich O., Henderson D.C., Walsh J.P., Culhane M.A., Goff D.C.Risperidone augmentation for schizophrenia partially responsive to clozapine: a doubleblind, placebo-controlled trial // Schizophrenia Bulletin. - 2007.
- V. 9(1-3). - P. 90-4.114. Fu Y., Fan C.H., Deng H.H., Hu S.H., Lv D.P., Li L.H., Wang J.J., Lu X.Q.Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia inChinese schizophrenic patients // Acta pharmacologica Sinica. - 2006.
- V. 27(3). - P.328-32.115. Fung D., Sreedharan S. Mental Health Trigger Tool (MHTT) A Novel Way toIdentify and Monitor Adverse Events in Mental Health Settings Institute of MentalHealth,Singapore.07Dec2014Availableat:http://app.ihi.org/FacultyDocuments/Events/Event-2491/Presentation-10515/Document9025/Presentation_L15_Presentation_Update_D._Fung_1207.pdf116. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation //International Review of Psychiatry. - 2013. - V.
25. - P. 534-53.117. Gaedigk A., Sangkuhl K., Whirl-Carrillo M., Klein T., Leeder J.S. Prediction ofCYP2D6 phenotype from genotype across world populations // Genetics in Medicine. 2017. - V. 19(1). - P. 69-76.118. Gaedigk A., Simon S.D., Pearce R.E., Bradford L.D., Kennedy M.J., Leeder J.S.The CYP2D6 activity score: translating genotype information into a qualitative measureof phenotype // Clinical Pharmacology & Therapeutics. - 2008. - V.
83(2). - P. 234-42.119. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M., Brockmöller J., Frotschl R.,Köpke K., Gerloff T., Chernov J.N., Roots I. Polymorphisms of drug-metabolizingenzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in aRussian population // European Journal of Clinical Pharmacology. - 2003.
- V. 59. - P.303-12.120. Gallego J.A., Bonetto J., Zhang J., Kane J.M., Correll C.U.. Prevalence andcorrelates of antipsychotic polypharmacy: a systematic review and meta-regression ofglobal and regional trends from the 1970s to 2009 // Schizophrenia Research. - 2012. V. 138. - P.
18-28.146121. Ganguly R., Kotzan J.A., Miller S., Kennedy K., Martin B.C. Prevalence, trends,and factors associated with antipsychotic polypharmacy among Medicaid-eligibleschizophrenia patients, 1998–2000 // The Journal of Clinical Psychiatry. - 2004. - V. 65.- P. 1377-88.122. Garrett Jr P.R., Sammer C., Nelson A., Paisley K.A., Jones C., Shapiro E., TonkelJ., Housman M. Developing and implementing a standardized process for global triggertool application across a large health system // Joint Commission Journal on Quality andPatient Safety. - 2013. - V. 39(7).
- P. 292-7.123. Gilmer T.P., Dolder C.R., Folsom D.P., Mastin W., Jeste D.V. Antipsychoticpolypharmacy trends among Medicaid beneficiaries with schizophrenia in San DiegoCounty, 1999-2004 // Psychiatric Services. - 2007. - V. 58(7). - P. 1007-10.124. Greenbaum L., Alkelai A., Zozulinsky P., Kohn Y., Lerer B. Support forassociation of HSPG2 with tardive dyskinesia in Caucasian populations // ThePharmacogenomics Journal. - 2012.
- V. 12(6). - P. 513-20.125. Greil W., Haag H., Rossnagl G., Rüther E. Effect of anticholinergics on tardivedyskinesia. A controlled discontinuation study // British Journal of Psychiatry. - 1984. Vol. 145 (3). - P. 304-310.126. Griese E.U., Zanger U.M., Brudermanns U., Gaedigk A., Mikus G., Mörike K.,Stüven T., Eichelbaum M. Assessment of the predictive power of genotypes for the invivo catalytic function of CYP2D6 in a German population // Pharmacogenetics. - 1998.- V. 8. - P.
15–26.127. Haddad P.M., Brain C., Scott J. Nonadherence with antipsychotic medication inschizophrenia: challenges and management strategies // Patient Related OutcomeMeasures. - 2014. - V. 5. - P. 43-62.128. Haddad P.M., Das A., Keyhani S., Chaudhry I.B. Antipsychotic drugs andextrapyramidal side effects in first episode psychosis: a systematic review of head-headcomparisons // Journal of Psychopharmacology. - 2012.
- V. 26(5 Suppl). - P. 15-26.129. Hakkarainen K.M., Andersson Sundell K., Petzold M., Hägg S. Methods forassessing the preventability of adverse drug events: a systematic review // Drug Safety.- 2012. - V. 35. - P. 105-26.147130. Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels inpatientswithschizophrenia:mechanismsandrelatedadverseeffects//Psychoneuroendocrinology. - 2003. - V.
28. - P. 53-67.131. Hall D.A., Agarwal P., Griffith A., Segro V., Seeberger L.C. Movement disordersassociated with aripiprazole use: a case series // International Journal of Neuroscience. 2009. - V. 119(12). - P. 2274-9.132. Hamann J., Kolbe G., Cohen R., Leucht S., Kissling W. How do psychiatristschoose among different antipsychotics? // European Journal of Pharmacology. - 2005. V. 61. - P.
851-4.133. Harris E., Barraclough B. Excess mortality of mental disorder // British Journal ofPsychiatry. - 1998. - V. 173. - P.11-53.134. Hasan S., Buckley P. Novel Antipsychotics and the Neuroleptic MalignantSyndrome: A Review and Critique // American Journal of Psychiatry. - 1998. - V. 155. P. 1113-6.135. Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity ofcost-effectiveness models // Pharmacoeconomics.
- 2005. - V. 23(Supple). - P. 3-16.136. Henderson J.B., Labbate L., Worley M. A case of acute dystonia after single doseof aripiprazole in a man with cocaine dependence // American Journal on Addictions. 2007. - V. 16(3). - P. 244.137. Hennessy S., Bilker W.B., Knauss J.S., Margolis D.J., Kimmel S.E., ReynoldsR.F., Glasser D.B., Morrison M.F., Strom B.L. Cardiac arrest and ventriculararrhythmia in patients taking antipsychotic drugs: cohort study using administrative data// British Medical Journal. - 2002.
- V. 325. - P. 1070-2.138. Higashi K., Medic G., Littlewood K.J., Diez T., Granström O., De Hert M.Medicationadherenceinschizophrenia:factorsinfluencingadherenceandconsequences of nonadherence, a systematic literature review // Therapeutic Advancesin Psychopharmacology. - 2013. - V. 3(4). - P.
200-18.139. Honer W.G., Thornton A.E., Chen E.Y., Chan R.C., Wong J.O., Bergmann A.,Falkai P., Pomarol-Clotet E., McKenna P.J., Stip E., Williams R., MacEwan G.W.,Wasan K., Procyshyn R. Clozapine alone versus clozapine and risperidone with148refractory schizophrenia.
Clozapine and Risperidone Enhancement (CARE) StudyGroup // New England Journal of Medicine - 2006. - V. 354(5). - P. 472-82.140. http://www.g-standaard.nl/risicoanalyse/B0004642.PDF(датаобращения07.02.2017).141. http://www.ncbi.nlm.nih.gov/SNP.
(дата обращения 15.06.2015).142. Hunter R., Kennedy E., Song F., Gadon L., Irving C.B. Risperidone versustypical antipsychotic medication for schizophrenia. Cochrane Database of SystematicReviews 2003, Issue 2. Art. No.: CD000440. DOI: 10.1002/14651858.CD000440.143. Hutton P., Taylor P.J., Mulligan L., Tully S., Moncrieff J.
Quetiapine immediaterelease v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal //British Journal of Psychiatry. - 2015. - V. 206(5). - P. 360-70.144. Jessen F., Kaduszkiewicz H., Daerr M., Bickel H., Pentzek M., Riedel-Heller S.,Wagner M., Weyerer S., Wiese B., van den Bussche H., Broich K., Maier W.Anticholinergic drug use and risk for dementia: target for dementia prevention //European Archives of Psychiatry and Clinical Neuroscience.
- 2010. - V. 260 (2). - P.111-5.145. Johansson I., Oscarson M., Yue Q.Y., Bertilsson L., Sjöqvist F., IngelmanSundberg M. Genetic analysis of the Chinese cytochrome P4502D locus:characterization of variant CYP2D6 genes present in subjects with diminished capacityfor debrisoquine hydroxylation // Molecular Pharmacology. - 1994. - V.46(3). - P.452-9.146. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., MurrayR.M., Markwick A., Lewis S.W.
Randomized controlled trial of the effect on quality oflife of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility ofthe Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) // Archives ofGeneral Psychiatry. -2006. - V. 63. - P. 1079-87.147. Joukamaa M., Helovaara M., Knekt P., Aromaa A., Raitasalo R., Lehtinen V.Schizophrenia, neuroleptic medication and mortality // British Journal of Psychiatry.
2006. - V. 188. - P. 122-7.149148. Kamishima K., Ishigooka J., Komada Y. Long term treatment with risperidonelong-acting injectable in patients with schizophrenia // Japanese Journal of Psychiatryand Neurology. - 2009. - V. 12. - P. 1223-44.149. Kantrowitz J.T., Citrome L. Olanzapine: review of safety // Expert Opinion onDrug Safety. - 2008. - V. 7(6). - P.
761-9.150. Kapur S., Mamo D. Half a century of antipsychotics and still a central role fordopamine D2 receptors // Progress in Neuro-Psychopharmacology & BiologicalPsychiatry. - 2003. - V. 27. - P. 1081-90.151. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptorexplain the action of atypical antipsychotics? A new hypothesis // American Journal ofPsychiatry. - 2001. - V. 158.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
